FDA Approves New Combination Pill for Suppressed HIV Treatment

The U.S. Food and Drug Administration has approved a new once-daily combination pill, bictegravir-lenacapavir, for adults with suppressed HIV. This therapy offers an alternative for patients experiencing prior drug resistance or tolerability issues with existing treatments. Its introduction as the smallest single-tablet regimen expands accessible treatment choices for managing HIV.